Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Effect of Functional Beverage on Weight Control and Body Fat Mass in Overweight Women

  • Chae, Jey-Sook (Research Institute of Science for Aging, Yonsei University) ;
  • Lee, Jong-Ho (Department of Food ＆ Nutrition, Yonsei University) ;
  • Koh, Soo-Jeong (Department of Food ＆ Nutrition, Yonsei University) ;
  • Jang, Yong-Soo (Division of Cardiology, Cardiovascular Genome Center, Yonsei Medical Institute, Yonsei University) ;
  • Lee, Jin-Hee (Nutraceuticals ＆ Functional Foods Division, CJ Foods R ＆ D, CJ Corp)
  • Published : 2003.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Carnitine, hydroxycitric acid, and soy peptide have been known to be anti-obesity agents. The purpose of this study was to evaluate the combined effects of carnitine, hydroxycitric acid, and soy peptide mixture as a potential anti-obesity supplement in overweight women. Overweight premenopausal women (n=33; PIBW>110; 20 to 39 years) were randomized into two groups: the placebo group and the functional beverage group (the test group). Functional beverage was composed of 2000 mg soy peptide, 20 mg L-carnitine and 300 mg garcinia(40% hydroxycitric acid). Body weight and 3 day food dimes, biochemical measurements and computerized tomography were measured at baseline and 8-week. After 8-week consumption of functional beverage with usual diet and exercise, body weight fell an average of 1.4 kg (2.1%). Visceral fat area reduced an average of 7.8% at L1($69.6{\pm}8.7\;vs\;64.2{\pm}7.5\;\textrm{cm}^2$) and 5.1% ($60.7{\pm}4.9\;vs\;57.6{\pm}4.8\;\textrm{cm}^2$, p<0.05) at L4level after weight loss in the test group. Calf fat area in the test group showed about 10% reduction ($31.0{\pm}2.7\;vs=\;27.7{\pm}1.7\;\textrm{cm}^2$, p<0.05) after weight loss. These reductions in fat areas were not shown in the placebo group. There were tendencies of increase in serum levels of $\beta-hydroxybutyrate$, acetoacetate, and total ketones in the test group. There were 7% and 17% insignificant increase in fasting free fatty acid (FFA) and response area of FFA during oral glucose tolerance test(OGTT), respectively, in this group. ill addition, little weight loss in the test group showed 8% but not significant reduction in insulin response area during OGTT. In conclusion, this study shows that taking a mixture of carnitine, hydroxycitric acid, and soy peptide as a potential anti-obesity supplement for 8-week produced advantageous changes in the weight and visceral fat accumulation of overweight women.

Keywords

References

  1. Badmaev, V. and Majeed, M. (1995). Open field, Physician controlled, clinical evaluation of botanical weight loss formula citrin. Presented at: Nutracon: Nutriceuticals, Dietary Supplementas and Functional Foods. Las Vegas, Nev.
  2. Bray, G. A. and Greenway, F. L. (1999). Current and potential drugs for treatment of obesity. Endocr. Rev. 20, 805-75 https://doi.org/10.1210/er.20.6.805
  3. Bremer, J. (1983). Camitine-metabolism and functions. Physiol. Rev. 63, 1420-80
  4. Chan, M. K., Persaud, J. W., Varghese, Z., Baillod, R. A. and Moorhead, J, P. (1982). Response patterns to DL-caruitine in patients on maintenance haemodialysis. Nephron. 30, 240-3 https://doi.org/10.1159/000182473
  5. Clouatre, D. and Rosenbaum, M. (1994). The diet and health benefits of HCA (Hydroxycitric acid); Keats Publishing, New Cannan, CT.
  6. Conte, A. A. (1993). A non-prescription alternative on weight reduction therapy. Am. J. Bariatr. Med. Summer, 17-9
  7. Crayhon, R. (1999). Camitine; Case histones. TotaI Health; Woodtand Hills. 21, 65-6
  8. Elisaf, M., Bairaktari, E., Katopodis, K., Pappas, M., Sferopoulos, G., Tzallas, C., Tsolas, O. and Siamopoulos, K. C. (1998). Effect of L-camitine supplementation on lipid parameters in hemodialysis patients. Am. J. Nephrol. 18, 416-21 https://doi.org/10.1159/000013386
  9. Field, A. E., Coakley, E. H., Must, A., Spadano, J. L., Laird, N., Dietz, W. H., Rimm, E. and Colditz, G. A. (2001), Impact of overweight on the risk of developing cominon chronic diseases during a lO-year period. Arch. Intern. Med. 161, 1581-6 https://doi.org/10.1001/archinte.161.13.1581
  10. Friedman, M., Byers, S. O., Rosenman, R. H. and Li, C. H. (1972). Hypocholesteroleimc effect of human growth hormone in coronary. Prone (type A) hypercholesterolemjc subjects. Proc. Soc. Exp. Biol. Med. 141, 76-80 https://doi.org/10.3181/00379727-141-36719
  11. Guamieri, G. F., Ranieri, F., Toigo, G., Vasile, A., Ciman, M., Rizzoli, V., Moracchiello, M. and Campanacci, L. (1980). Lipid-lowring effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am. J. Clin. Nutr. 33, 1489-92
  12. Heymsfield, S. B., Allison, D. B., Vasselli, J. R., Pietrobelli, A., Greenfield, D., Nunez, C. (1998). Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 280, 1596-600 https://doi.org/10.1001/jama.280.18.1596
  13. Hoppel, C. L, and Genuth, S. M. (1980). Camitine metabolism in normal-weight and obese human subjects during fasting. Am. J. Physiol. 238, E409-15
  14. Jena, B. S., Jayaprakasha, G. K., Singh, R. P. and Sakariah, K. K. (2002). Chemistry and biochemistry of (-)-hydroxycitric acid from Garcinia. J. Agric. Food. Chem. 50, 10-22 https://doi.org/10.1021/jf010753k
  15. Klauer, J. and Aronne, L. J. (2002). Managing overweight and obesity in women. Clin. Obstel. Gynecol. 45, 1080-8 https://doi.org/10.1097/00003081-200212000-00016
  16. Lowenstein, J. M. (1971). Effect of (-)-hydroxycitrate on fatly acid synthesis by rat liver in vivo. J. Biol Chem. 246, 629-32
  17. Ministry of Health and Social Affirs. (1990). National Survey Report.
  18. Ministry of Health and Social Affirs. (2000). National Survey Report
  19. Muramatsu, S., Yamazaki, S. and Hattori, Y. (1994). Effect of soy-peptine intake for long term xercise perforimances of Judo atheletes. Chiba. J. Physiol. Educat. 18, 41-8
  20. Noel, P. H. and Pugh, J. A. (2002). Management of overweight and obese adults. BMJ. 325, 757-61 https://doi.org/10.1136/bmj.325.7367.757
  21. Perusse, L. and Bouchard, C. (1999). Genotype-environment interaction in hyman obesity. Nutr. Rev. 57, s31-s37 https://doi.org/10.1111/j.1753-4887.1999.tb01785.x
  22. Shick, S. M., Wing, R. R., Klem, M. L., McGure, M. T., Hill, J. O. and Seagle, H. (2002). Persons successful at long-term weight loss and maintenance continue to consume a lowenergy, low-fat diet. J. Am. Diet. Assoc. 98, 408-13 https://doi.org/10.1016/S0002-8223(98)00093-5
  23. Sullivan, A. C, Triscari, J., Hamilton, J. G., Miller, O. N. and Wheatley, V. R. (1974). Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. I. Lipogenesis. Lipids. 9, 121-8
  24. Thom, E. (1996), Hydroxycitrate (HCA) in the treatment of obesity. Int. J. Obes. 20(supp1e 4), 48
  25. Triscan, J. and Sullivan, A. C. (1997). Comparative effects of (1)-hydroxycitraie and (+)-a11o-hydroxycitiate on acetyl CoA car boxylase and fatty acid and cholesterol synthesis in vivo. Lip-ids. 12, 357-63
  26. Vacha, G. M., Giorcelli, G., D'lddio, S. and Corsi, M. (1985). Effect of long-term treatment with L-camitine on the lipid pat-tern of patients undergoing heamodialysis. Proc. Eur. Dial. transplant. Assoc. 22, 121-6
  27. Villani, R. G., Gannon, J., Self, M. and Rich, P. A. (2000). L-Car-nitine supplementauon combined with aerobic training does not promote weight loss in moderately obese women, Int. J. Sport. Nutr. Exerc. Metab. 10, 199-207
  28. Wanner, C, Wieland, H., Wackerle, B., Boeckle, H., Schollmeyer, P. and Horl, W. H. (1989). Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients. Kidney. Int. Suppt. 27, S264-8
  29. Weschler, A., Aviram, M., Levin, M., Better, O. S. and Birook, J. G. (1984). High dose of L-camitine increases platelet aggregation and plasma tnglyceride levels in uremic patients on hemodialysis. Nephron. 38, 120-4 https://doi.org/10.1159/000183292